UKZN PhD Graduate Advances HIV Drug Resistance Research with Ground-breaking Study

BY: .

The University of KwaZulu-Natal (UKZN) has celebrated the remarkable achievement of Dr Melendhran Pillay, who graduated with a PhD in Virology for his pioneering research into HIV drug resistance and treatment failure in KwaZulu-Natal.

Pillay’s doctoral study, titled: ‘The Diversity and Impact of Drug-Resistant Mutations in Virologic Failure on First-Line Antiretroviral Therapy in KwaZulu-Natal’, offers critical new insights into why some patients experience failure on antiretroviral therapy (ART), despite standard diagnostic testing.

A Senior Medical Scientist at the National Health Laboratory Service (NHLS), Pillay focused his research on HIV-1 drug resistance using advanced Next Generation Sequencing (NGS) techniques. His work employed a sophisticated ‘Primer ID’ approach to uncover the complex viral diversity known as quasispecies, within patients failing treatment.

“I am incredibly proud to share the culmination of my PhD research,” said Pillay. “We uncovered a level of viral diversity that traditional methods simply failed to detect. This represents a significant milestone in refining HIV drug resistance monitoring in sub-Saharan Africa.”

His findings revealed that HIV exists as a highly complex mixture of variants within individuals, with a median of 10 different resistance patterns per patient. Notably, 67% of these patterns involved linked dual-class drug resistance mutations, something standard Sanger sequencing methods often miss.

To address this gap, Pillay developed a novel weighted Genotypic Susceptibility Score (wGSS), which more accurately predicts treatment outcomes. His research demonstrated that lower wGSS scores are strongly associated with persistent virologic failure, offering clinicians a more precise tool for guiding patient care.

“This work provides a tangible link between advanced laboratory methods and clinical outcomes,” he explained. “It gives us a clearer understanding of why certain patients continue to fail therapy and how we can better intervene.”

Importantly, the study is considered novel, providing proof-of-principle evidence of previously underappreciated intra-host HIV diversity. By optimising the NGS-Primer ID assay for HIV-1 subtype C, which is the most prevalent strain in the region, Pillay ensured the research is directly relevant to the sub-Saharan African context.

His academic journey also included time at Harvard University, where he refined his experimental techniques to meet international standards, all while maintaining his demanding diagnostic responsibilities at the NHLS.

Pillay credits his passion for virology to his frontline experience in diagnostic laboratories. “I have seen first-hand the challenges patients face when ART fails. I wanted to bridge the gap between routine diagnostics and advanced research to improve long-term treatment outcomes,” he said.

Despite encountering technical challenges, particularly in amplifying HIV-1 subtype C variants, he successfully overcame these through rigorous optimisation, demonstrating both scientific innovation and resilience.

Reflecting on his time at UKZN, Pillay described it as transformative. “Being at the forefront of HIV research in a region most affected by the epidemic provided a unique sense of purpose. The environment encouraged innovation and allowed me to adapt complex tools to solve local challenges.”

Currently, Pillay supervises the HIV Drug Resistance and Viral Polymerase Chain Reaction (PCR) molecular sections at the NHLS Virology Laboratory at Inkosi Albert Luthuli Central Hospital (IALCH) and remains actively involved in teaching and mentoring students at UKZN.

He expressed deep gratitude to his supervisor, Dr Nokukhanya Msomi, co-supervisors Dr Pravi Moodley and Professor Jonathan Zheng Li, and collaborator, Dr Aabida Khan, for their unwavering support.

Msomi praised his work, noting: “His PhD described an innovative way to detect mutations that occur at low frequencies and are not easily identified using traditional methods. He balanced service commitments and academic demands with exceptional dedication.”

As HIV drug resistance continues to pose a major challenge globally, particularly in sub-Saharan Africa, Pillay’s research represents a significant step forward in improving diagnostic precision and patient care.

“We are honoured to contribute these findings to the field of virology,” he said. “This is just the beginning of our work to ensure more precise and effective ART for those who need it most.”

Words: MaryAnn Francis

Photograph: Sethu Dlamini